LSTA Lisata Therapeutics Inc

$LSTA Is this getting cheap again?? Not as simple a set-up as before. But the merged company will be a very decent company with great assets and runway through 2028. Funding at $1.49 ($225M).

$LSTA For my fellow Lisata-ians, I see $LGVN now as the new LSTA when LSTA was trading at $1.0/share. See my post in the LGVN chat but I think it's a great opportunity for those looking to slowly shift out of LSTA into another similar play. Cash strapped strategic alternative play w/ a more valuable drug than Certepetide imo.

$LSTA kuva's original offer was over 6 simes higher than now. I find it hard to believe that the new offer they made was lower than 1$ so it looks like CEO is once again actain against shareholders best interests. I think Marea shareholders should be worried to merge business with Mr. Mazzo.

$LSTA 52 week low appears to be holding… for now. The precipitous drop however gives me the feeling we’re going to see the floor break sometime this week

$LSTA Could it be that this going down due to the planned RS for the merger?? (silly if yes)

$LSTA what a frikkin bust hope you sucker buyers didn't pay 1.50 for these toxic shares 2.5% of the new company !!! ahhhhhhhhh

$LSTA Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors

$LSTA Preliminary proxy for shareholder meeting scheduled Nov 9 https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126038937/ny20082391x1_pre14a.htm Shareholders are being asked to: 1) Elect Cynthia Flowers and Ted Love as Directors 2) Ratify Grant Thornton LLP as independent auditor 3) Approve the Series C Non-Voting Convertible Preferred Stock issued as part of the Marea acquisition & PIPE. 4) Approve a reverse split in the range of 1:5 to 1:10. 5) Approve the 2026 Equity Incentive Plan 6) Approve the 2026 ESPP 7) Approve executive compensation. Non-binding "say on pay" 8) Approve an adjournment if they do not have enough votes to pass Proposals 3-6.

$LSTA not too much to say at this point sub 1 plus a r/s almost a certainty just look at the history here scammy, and may be close to the record for name changes over time

$LSTA About MAR001/005 MAR001 is a potential first-in-class monoclonal antibody in clinical development that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower triglycerides and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower triglyceride levels, improved adipose distribution, better insulin sensitivity, and protection from cardiovascular disease and type 2 diabetes

$LSTA the only thing i'm curios about this company is to read in next sec filings whether Kuva did or didnt make an offer.